Overview
- Eli Lilly became the first publicly traded health-care company to touch $1 trillion in market value on Nov. 21 before the stock eased to trade near $1,000.
- Q3 results showed $6.5 billion in Mounjaro sales and $3.6 billion for Zepbound, driving 54% revenue growth to $17.6 billion and propelling tirzepatide to the year’s top-selling drug status.
- Over the first nine months of 2025, combined Mounjaro and Zepbound sales reached nearly $19 billion, surpassing Merck’s Keytruda by product sales.
- Lilly and Novo Nordisk agreed with the Trump administration to lower prices for Medicare and Medicaid in exchange for broader coverage, with implementation details still unfolding.
- Bernstein raised its price target to $1,300 and JPMorgan to $1,150, as Lilly advances plans to submit oral orforglipron for obesity by year-end and expands manufacturing to boost supply.